NCT05681780 2025-12-04Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCH. Lee Moffitt Cancer Center and Research InstitutePhase 1 Active not recruiting13 enrolled